JP2009529058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009529058A5 JP2009529058A5 JP2008558415A JP2008558415A JP2009529058A5 JP 2009529058 A5 JP2009529058 A5 JP 2009529058A5 JP 2008558415 A JP2008558415 A JP 2008558415A JP 2008558415 A JP2008558415 A JP 2008558415A JP 2009529058 A5 JP2009529058 A5 JP 2009529058A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aptamer
- agent
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 43
- 229920002395 Aptamer Polymers 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 208000002780 Macular Degeneration Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 6
- 108090001123 antibodies Proteins 0.000 claims 6
- 102000004965 antibodies Human genes 0.000 claims 6
- 230000002391 anti-complement Effects 0.000 claims 5
- 108010008730 anticomplement Proteins 0.000 claims 5
- 108010087870 Mannose-Binding Lectin Proteins 0.000 claims 4
- 102000009112 Mannose-Binding Lectin Human genes 0.000 claims 4
- 210000001210 Retinal Vessels Anatomy 0.000 claims 4
- 230000000295 complement Effects 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000001189 Cyclic Peptides Human genes 0.000 claims 3
- 108010069514 Cyclic Peptides Proteins 0.000 claims 3
- 208000009745 Eye Disease Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000025458 RNA interference Effects 0.000 claims 3
- 230000000692 anti-sense Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrugs Drugs 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 102100007517 C5 Human genes 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000004438 eyesight Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000004304 visual acuity Effects 0.000 claims 2
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 1
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 claims 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 102100012590 C3 Human genes 0.000 claims 1
- 101710042991 C3AR1 Proteins 0.000 claims 1
- 101700049499 C5AR1 Proteins 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 108090000056 Complement Factor B Proteins 0.000 claims 1
- 102000003712 Complement Factor B Human genes 0.000 claims 1
- 108090000059 Complement Factor D Proteins 0.000 claims 1
- 102000003706 Complement Factor D Human genes 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 210000004087 Cornea Anatomy 0.000 claims 1
- 206010011017 Corneal graft rejection Diseases 0.000 claims 1
- 208000001763 Cytomegalovirus Retinitis Diseases 0.000 claims 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014801 Endophthalmitis Diseases 0.000 claims 1
- 206010018258 Giant papillary conjunctivitis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101710015954 HVA1 Proteins 0.000 claims 1
- 206010061217 Infestation Diseases 0.000 claims 1
- 101710041880 Jon99Cii Proteins 0.000 claims 1
- 206010023332 Keratitis Diseases 0.000 claims 1
- 101700065814 LEA2 Proteins 0.000 claims 1
- 101700021338 LEC Proteins 0.000 claims 1
- 101700077545 LECC Proteins 0.000 claims 1
- 101700028499 LECG Proteins 0.000 claims 1
- 101700063913 LECT Proteins 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010030032 Ocular disorder Diseases 0.000 claims 1
- 101710034340 Os04g0173800 Proteins 0.000 claims 1
- 101710042137 PRSS1 Proteins 0.000 claims 1
- 102100008350 PRSS1 Human genes 0.000 claims 1
- 101710042136 PRSS2 Proteins 0.000 claims 1
- 102100005192 PRSS2 Human genes 0.000 claims 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 claims 1
- 101700044242 SER2 Proteins 0.000 claims 1
- 101700029146 SFAS1 Proteins 0.000 claims 1
- 101700026651 SFAS2 Proteins 0.000 claims 1
- 101700079296 SP1 Proteins 0.000 claims 1
- 101700063611 SUB1 Proteins 0.000 claims 1
- 101700083576 SUB2 Proteins 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010062766 Stargardt's disease Diseases 0.000 claims 1
- 206010062958 Subretinal fibrosis Diseases 0.000 claims 1
- 206010068760 Ulcers Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 241000282485 Vulpes vulpes Species 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 101700036391 lecA Proteins 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 101700001016 mbhA Proteins 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 244000045947 parasites Species 0.000 claims 1
- 150000004033 porphyrin derivatives Chemical group 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
- 201000011056 retinal disease Diseases 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Claims (31)
- 眼障害を処置、安定化および／または予防するための組成物であって、治療有効量の抗補体アプタマーを含む、組成物。
- 前記眼障害が、新生血管形成眼障害である、請求項１に記載の組成物。
- 処置される前記眼障害が、黄斑変性、糖尿病性網膜症、加齢性黄斑変性（ＡＭＤ）または滲出型のＡＭＤである、請求項１に記載の組成物。
- 処置される前記眼障害が、アレルギー性結膜炎および巨大乳頭性結膜炎を含む炎症性結膜炎、黄斑浮腫、ブドウ膜炎、眼内炎、強膜炎、角膜の潰瘍、ドライアイ症候群、緑内障、虚血性網膜疾患、角膜移植片拒絶、眼内レンズ移植などの眼内手術に関連する合併症および白内障手術に伴う炎症、ベーチェット病、シュタルガルト病、免疫複合体脈管炎、フックス病、フォークト−小柳−原田病、網膜下線維症、角膜炎、硝子体網膜炎症、眼の寄生虫の外寄生／移動、色素性網膜炎、サイトメガロウイルス網膜炎または脈絡膜の炎症である、請求項１に記載の組成物。
- 前記組成物が、該組成物の投与前の被験体の視力レベルと比較して該被験体において少なくとも同じレベルの視力を維持するのに有効な量で投与されることを特徴とする、請求項１、２、３または４に記載の組成物。
- 前記組成物が、該組成物の投与前の被験体の網膜血管密度とほぼ同じレベルの該被験体の網膜血管密度を維持するのに有効な量で投与されることを特徴とする、請求項１、２、３、４または５に記載の組成物。
- 前記抗補体アプタマーが、膜攻撃経路の成分を阻害するアプタマーである、請求項１〜６のいずれかに記載の組成物。
- 前記抗補体アプタマーが、古典的補体経路の成分、第二補体経路の成分、またはレクチン経路の成分を阻害するアプタマーである、請求項１〜７のいずれかに記載の組成物。
- 前記抗補体アプタマーが、Ｃ１、Ｃ１ｑ、Ｃ１ｒ、Ｃ１ｓ、Ｃ２、Ｃ３、Ｃ３ａ、Ｃ３ａレセプター、Ｃ４、Ｃ５、Ｃ５ａ、Ｃ５ａレセプター、Ｃ５ｂ、Ｃ６、Ｃ７、Ｃ８、Ｃ９、Ｂ因子、Ｄ因子、プロペルジン、マンナン結合レクチン（ＭＢＬ）、ＭＢＬ結合型セリンプロテアーゼ１またはＭＢＬ結合型セリンプロテアーゼ２の補体成分標的に結合してそれを阻害するアプタマーである、請求項１〜８のいずれかに記載の組成物。
- 前記補体成分標的が、ヒトの標的タンパク質である、請求項１〜９のいずれかに記載の組成物。
- 前記抗補体アプタマーが、Ｃ５を阻害するアプタマーである、請求項１〜１０のいずれかに記載の組成物。
- Ｃ５結合アプタマーが、配列番号１〜６９、７５、７６、８１、９１、９５または９６の配列を有する、請求項１１に記載の組成物。
- 前記組成物が、デポー製剤中で投与されることを特徴とする、請求項１〜１２のいずれか１項に記載の組成物。
- 前記被験体が、ヒトである、請求項５〜１３のいずれかに記載の組成物。
- 眼障害を処置するための組成物であって、治療有効量の抗Ｃ５剤を含む、組成物。
- 前記眼障害が、新生血管形成眼障害である、請求項１５に記載の組成物。
- 処置される前記眼障害が、黄斑変性、糖尿病性網膜症、加齢性黄斑変性（ＡＭＤ）または滲出型のＡＭＤである、請求項１６に記載の組成物。
- 前記組成物が、該組成物投与前の被験体の視力レベルと比較して該被験体において少なくとも同じレベルの視力を維持するのに有効な量で投与されることを特徴とする、請求項１５、１６または１７に記載の組成物。
- 前記組成物が、該組成物の投与前の被験体の網膜血管密度とほぼ同じレベルの該被験体の網膜血管密度を維持するのに有効な量で投与されることを特徴とする、請求項１５、１６または１７に記載の組成物。
- 抗ＶＥＧＦ剤をさらに含む、請求項１５〜１９のいずれか１項に記載の組成物。
- 前記抗ＶＥＧＦ剤が、核酸分子、アプタマー、アンチセンス分子、ＲＮＡｉ分子、タンパク質、ペプチド、環状ペプチド、抗体または抗体フラグメント、糖、ポリマーまたは小分子である、請求項２０に記載の組成物。
- 抗ＰＤＧＦ剤をさらに含む、請求項１５〜２１のいずれか１項に記載の組成物。
- 前記抗ＰＤＧＦ剤が、核酸分子、アプタマー、アンチセンス分子、ＲＮＡｉ分子、タンパク質、ペプチド、環状ペプチド、抗体または抗体フラグメント、糖、ポリマーまたは小分子である、請求項２２に記載の組成物。
- 前記抗Ｃ５剤が、核酸分子、アプタマー、アンチセンス分子、ＲＮＡｉ分子、タンパク質、ペプチド、環状ペプチド、抗体または抗体フラグメント、糖、ポリマーまたは小分子である、請求項１５〜２３のいずれかに記載の組成物。
- 前記抗Ｃ５剤が、Ｃ５特異的アプタマーである、請求項１５〜２４のいずれかに記載の組成物。
- 前記Ｃ５特異的アプタマーが、配列番号１〜６７、７５〜８１または８８〜９８の配列を有する、請求項２５に記載の組成物。
- 前記抗Ｃ５剤が、プロドラッグである、請求項１５〜２６のいずれかに記載の組成物。
- 前記抗ＶＥＧＦ剤が、プロドラッグである、請求項２０〜２７のいずれかに記載の組成物。
- 前記抗ＰＤＧＦ剤が、プロドラッグである、請求項２２〜２８のいずれかに記載の組成物。
- 抗血管形成剤をさらに含む、請求項１５〜２９のいずれか１項に記載の組成物。
- 前記抗血管形成剤が、ポルフィリン誘導体である、請求項３０に記載の組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78090506P | 2006-03-08 | 2006-03-08 | |
| US60/780,905 | 2006-03-08 | ||
| US84827406P | 2006-09-29 | 2006-09-29 | |
| US60/848,274 | 2006-09-29 | ||
| PCT/US2007/006020 WO2007103549A2 (en) | 2006-03-08 | 2007-03-08 | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013004412A Division JP5746232B2 (ja) | 2006-03-08 | 2013-01-15 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009529058A JP2009529058A (ja) | 2009-08-13 |
| JP2009529058A5 true JP2009529058A5 (ja) | 2010-04-22 |
| JP5406534B2 JP5406534B2 (ja) | 2014-02-05 |
Family
ID=38475591
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558415A Active JP5406534B2 (ja) | 2006-03-08 | 2007-03-08 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
| JP2013004412A Active JP5746232B2 (ja) | 2006-03-08 | 2013-01-15 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
| JP2014126169A Withdrawn JP2014172910A (ja) | 2006-03-08 | 2014-06-19 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013004412A Active JP5746232B2 (ja) | 2006-03-08 | 2013-01-15 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
| JP2014126169A Withdrawn JP2014172910A (ja) | 2006-03-08 | 2014-06-19 | 補体結合アプタマーおよび眼障害の処置において有用な抗ｃ５剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20090269356A1 (ja) |
| EP (5) | EP4159220A1 (ja) |
| JP (3) | JP5406534B2 (ja) |
| KR (3) | KR101584468B1 (ja) |
| CN (1) | CN104623692A (ja) |
| AU (1) | AU2007223796B2 (ja) |
| BR (1) | BRPI0708588A2 (ja) |
| CA (4) | CA3148917A1 (ja) |
| DK (2) | DK2596807T3 (ja) |
| ES (2) | ES2562423T3 (ja) |
| HK (3) | HK1181308A1 (ja) |
| HU (1) | HUE026496T2 (ja) |
| IL (1) | IL193828A (ja) |
| MX (1) | MX2008011323A (ja) |
| NZ (1) | NZ571791A (ja) |
| PL (2) | PL1991275T3 (ja) |
| PT (2) | PT1991275E (ja) |
| RU (2) | RU2477137C2 (ja) |
| SG (3) | SG172686A1 (ja) |
| SI (2) | SI2596807T1 (ja) |
| WO (1) | WO2007103549A2 (ja) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| EP2371865B1 (en) | 2006-04-07 | 2017-07-12 | Aerpio Therapeutics, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| EP2562256A3 (en) * | 2007-09-24 | 2013-06-19 | Noxxon Pharma AG | C5a binding nucleic acids |
| US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| TW200927169A (en) * | 2007-11-07 | 2009-07-01 | Alcon Res Ltd | Complement Clq inhibitors for the prevention and treatment of glaucoma |
| WO2009061910A1 (en) | 2007-11-08 | 2009-05-14 | Genetech, Inc. | Anti-factor b antibodies and their uses |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| NZ588507A (en) | 2008-04-11 | 2012-11-30 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US9891219B2 (en) | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
| US20110125090A1 (en) * | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
| WO2010108657A2 (en) * | 2009-03-23 | 2010-09-30 | Noxxon Pharma Ag | C5a binding nucleic acids and the use thereof |
| BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
| US9408746B2 (en) | 2010-03-31 | 2016-08-09 | Ocuject, Llc | Device and method for intraocular drug delivery |
| US9320647B2 (en) | 2010-03-31 | 2016-04-26 | Ocuject, Llc | Device and method for intraocular drug delivery |
| WO2012070618A1 (ja) | 2010-11-24 | 2012-05-31 | 株式会社カネカ | 増幅核酸検出方法及び検出デバイス |
| CN107973851A (zh) | 2010-11-30 | 2018-05-01 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| CA2823665A1 (en) | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| JP5937197B2 (ja) | 2011-04-08 | 2016-06-22 | ユニバーシティー オブ レスター | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2013201606B2 (en) * | 2011-04-08 | 2016-02-25 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2708233B1 (en) | 2011-05-13 | 2018-06-27 | The University of Tokyo | Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases |
| JP2014530244A (ja) | 2011-10-13 | 2014-11-17 | エアピオ セラピューティックス， インコーポレイテッド | 血管漏出症候群および癌を治療する方法 |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| AU2013209131A1 (en) | 2012-01-10 | 2014-07-10 | Noxxon Pharma Ag | New C5a binding nucleic acids |
| HUE039611T2 (hu) | 2012-01-27 | 2019-01-28 | Abbvie Deutschland | Készítmények és eljárások axondegenerációval járó betegségek diagnózisára és kezelésére |
| PT2817329T (pt) | 2012-02-20 | 2019-04-01 | Swedish Orphan Biovitrum Ab Publ | Polipeptioos que se ligam ao complemento humano c5 |
| US9504603B2 (en) * | 2012-04-02 | 2016-11-29 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
| US9421129B2 (en) * | 2012-04-02 | 2016-08-23 | Ocuject, Llc | Intraocular delivery devices and methods therefor |
| JP6219816B2 (ja) * | 2012-04-27 | 2017-10-25 | 株式会社カネカ | 核酸の増幅方法、および、増幅核酸の検出方法 |
| KR20200015952A (ko) * | 2012-06-18 | 2020-02-13 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| JP6155332B2 (ja) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| JP6214647B2 (ja) | 2012-06-28 | 2017-10-18 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| ES2644700T3 (es) | 2012-06-28 | 2017-11-30 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la ruta del complemento |
| ES2710491T3 (es) | 2012-06-28 | 2019-04-25 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| WO2014002052A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| AU2013288319A1 (en) | 2012-07-12 | 2015-02-05 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR20220139425A (ko) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| WO2014055835A1 (en) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| WO2014071206A1 (en) | 2012-11-02 | 2014-05-08 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| RU2663349C2 (ru) * | 2013-01-31 | 2018-08-03 | СЕУЛ НЭШНЛ ЮНИВЕРСИТИ Ар энд ДиБи ФАУНДЕЙШН | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний |
| SG11201507400SA (en) | 2013-03-14 | 2015-10-29 | Alnylam Pharmaceuticals Inc | Complement component c5 irna compositions and methods of use thereof |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| CA2915255A1 (en) | 2013-07-12 | 2015-01-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| MX2016002397A (es) * | 2013-08-28 | 2016-09-08 | Swedish Orphan Biovitrum Ab (Publ) | Union de polipeptidos estables al componente 5(c5) de complemento humano. |
| WO2015039126A1 (en) * | 2013-09-16 | 2015-03-19 | Children hospital medical center | Compositions and methods for treatment of hsct-associated thrombotic microangiopathy |
| AU2014332021B2 (en) * | 2013-10-07 | 2020-05-07 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
| US10392652B2 (en) | 2013-11-22 | 2019-08-27 | Kaneka Corporation | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end |
| US10183989B2 (en) | 2013-12-24 | 2019-01-22 | Novelmed Therapeutics, Inc. | Methods of treating ocular diseases |
| SG11201606379UA (en) * | 2014-02-05 | 2016-09-29 | Univ Deakin | Aptamer construct |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| EP3194596A1 (en) * | 2014-09-16 | 2017-07-26 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| BR112017005730B1 (pt) | 2014-09-26 | 2023-12-12 | Somalogic Operating Co., Inc | Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento |
| WO2016094834A2 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| PL3280440T3 (pl) | 2015-04-06 | 2023-06-19 | Bioverativ Usa Inc. | Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania |
| EP3307318A4 (en) | 2015-06-09 | 2019-01-16 | Children's Hospital Medical Center | DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR |
| JP6959924B2 (ja) | 2015-09-23 | 2021-11-05 | エアーピオ ファーマシューティカルズ， インコーポレイテッド | Ｔｉｅ−２の活性化物質を用いる眼内圧を処置する方法 |
| JP6088703B1 (ja) * | 2015-12-18 | 2017-03-01 | 中外製薬株式会社 | 抗ｃ５抗体および使用方法 |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| JP2019508405A (ja) | 2016-02-08 | 2019-03-28 | ヴィトリサ セラピューティクス， インコーポレイテッド | 改良された硝子体内半減期を有する組成物およびその使用 |
| RU2018146778A (ru) | 2016-06-07 | 2020-07-09 | Новартис Аг | Режим дозирования антитела к c5 |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| EP3592386A4 (en) | 2017-03-06 | 2021-01-13 | The Trustees Of The University Of Pennsylvania | ANTI-C5 ANTIBODIES AND THEIR USES |
| WO2019040397A1 (en) * | 2017-08-21 | 2019-02-28 | Ophthotech Corporation | METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE |
| EP3717004A4 (en) | 2017-12-01 | 2021-12-01 | Children's Hospital Medical Center | COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| EP3597222A1 (en) * | 2018-07-16 | 2020-01-22 | Easemedcontrol R & D GmbH & Co KG | Treatment and diagnosis of unresolved inflammatory diseases |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| CA3138682A1 (en) | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| AU2020378982A1 (en) * | 2019-10-27 | 2022-05-26 | Astellas Us Llc | Anti-C5 agent for treatment of dry age-related macular degeneration (AMD) or geographic atrophy secondary to dry AMD |
| RU2738001C1 (ru) * | 2020-03-23 | 2020-12-07 | Борис Сергеевич Першин | Способ определения риска развития цитомегаловирусного (ЦМВ) ретинита после трансплантации гемопоэтических стволовых клеток |
| WO2023044048A1 (en) | 2021-09-17 | 2023-03-23 | Novartis Ag | Methods for prevention of graft rejection in xenotransplantation |
| WO2023183556A2 (en) * | 2022-03-24 | 2023-09-28 | Amcyte Pharma, Inc. | Treatment for retinal disorders |
| WO2023212719A1 (en) * | 2022-04-29 | 2023-11-02 | Annexon, Inc. | Compositions and methods for treating ocular diseases |
| TW202415387A (zh) | 2022-06-30 | 2024-04-16 | 美商伊維希比奥公司 | 用於治療眼科疾患之持續釋放二氧化矽水凝膠複合物及其使用方法 |
| WO2024059873A2 (en) * | 2022-09-16 | 2024-03-21 | Sirnaomics, Inc. | Products and compositions |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US5212071A (en) | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
| US5981481A (en) * | 1974-12-06 | 1999-11-09 | The Johns Hopkins University | Human C3b/C4b receptor (CR1) |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4959309A (en) * | 1983-07-14 | 1990-09-25 | Molecular Diagnostics, Inc. | Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1986005803A1 (fr) * | 1985-03-30 | 1986-10-09 | Marc Ballivet | Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4935363A (en) * | 1987-03-30 | 1990-06-19 | Board Of Regents, The University Of Texas System | Sterol regulatory elements |
| US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5070010A (en) * | 1989-10-30 | 1991-12-03 | Hoffman-La Roche Inc. | Method for determining anti-viral transactivating activity |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US6140490A (en) | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5861254A (en) | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5660985A (en) * | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5707796A (en) * | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| US5654151A (en) * | 1990-06-11 | 1997-08-05 | Nexstar Pharmaceuticals, Inc. | High affinity HIV Nucleocapsid nucleic acid ligands |
| US6011020A (en) * | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5567588A (en) * | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5726017A (en) * | 1990-06-11 | 1998-03-10 | Nexstar Pharmaceuticals, Inc. | High affinity HIV-1 gag nucleic acid ligands |
| US5648214A (en) | 1990-06-11 | 1997-07-15 | University Research Corporation | High-affinity oligonucleotide ligands to the tachykinin substance P |
| US5543293A (en) * | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5789157A (en) * | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US6147204A (en) | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5503978A (en) * | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5527894A (en) * | 1990-06-11 | 1996-06-18 | Nexstar Pharmacueticals, Inc. | Ligands of HIV-1 tat protein |
| ATE160821T1 (de) | 1990-06-11 | 1997-12-15 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| US5476766A (en) * | 1990-06-11 | 1995-12-19 | Nexstar Pharmaceuticals, Inc. | Ligands of thrombin |
| US5580737A (en) * | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5668264A (en) * | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5635615A (en) * | 1990-06-11 | 1997-06-03 | Nexstar Pharmaceuticals, Inc. | High affinity HIV nucleocapsid nucleic acid ligands |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| US5252216A (en) | 1992-03-24 | 1993-10-12 | Smithkline Beecham Corporation | Protein purification |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| US5338671A (en) * | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| AU685433B2 (en) | 1993-02-12 | 1998-01-22 | Regents Of The University Of Minnesota | Pulmonary administration of sCR1 and other complement inhibitory proteins |
| US5428149A (en) * | 1993-06-14 | 1995-06-27 | Washington State University Research Foundation | Method for palladium catalyzed carbon-carbon coulping and products |
| RU2073518C1 (ru) * | 1993-06-17 | 1997-02-20 | Совместное русско-американское акционерное общество закрытого типа "Неофарм" | Средство, восстанавливающее функцию сетчатой оболочки глаза |
| CA2166805A1 (en) | 1993-07-09 | 1995-01-19 | Thomas M. Smith | Protein purification |
| US5817635A (en) | 1993-08-09 | 1998-10-06 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
| US6013443A (en) * | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| US6207816B1 (en) * | 1995-06-02 | 2001-03-27 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to growth factors |
| US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| DE69637805D1 (de) * | 1995-06-07 | 2009-02-26 | Gilead Sciences Inc | Nukleinsäure liganden die dna-polymerase binden und inhibieren |
| DE122006000029I2 (de) | 1996-10-25 | 2007-11-08 | Gilead Sciences Inc | Gefaesszellen Wachstumsfaktor (vegf) nukleinsäureligand-komplexe |
| US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US6251588B1 (en) * | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| WO2000037502A2 (en) * | 1998-12-22 | 2000-06-29 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| US20020102581A1 (en) * | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| WO2000060115A2 (en) | 1999-04-02 | 2000-10-12 | City Of Hope | Method for identifying accessible binding sites on rna |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
| DK2026073T3 (en) * | 2000-04-29 | 2016-07-25 | Univ Iowa Res Found | Diagnosis and treatment of macular degeneration-related disorders |
| US20020097419A1 (en) | 2001-01-19 | 2002-07-25 | Chang William Ho | Information apparatus for universal data output |
| AU2003247576A1 (en) * | 2002-06-18 | 2003-12-31 | Archemix Corp. | Aptamer-toxin molecules and methods for using same |
| US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| US7595430B2 (en) * | 2002-10-30 | 2009-09-29 | University Of Kentucky Research Foundation | Methods and animal model for analyzing age-related macular degeneration |
| WO2004047742A2 (en) * | 2002-11-21 | 2004-06-10 | Archemix Corporation | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same |
| CA2506748A1 (en) * | 2002-12-03 | 2004-06-17 | Archemix Corporation | Method for in vitro selection of 2'-substituted nucleic acids |
| US20050037394A1 (en) * | 2002-12-03 | 2005-02-17 | Keefe Anthony D. | Method for in vitro selection of 2'-substituted nucleic acids |
| AU2004206955A1 (en) * | 2003-01-21 | 2004-08-05 | Archemix Corp. | Aptamer therapeutics useful in ocular pharmacotherapy |
| CA2876822C (en) * | 2003-08-27 | 2015-11-17 | David Shima | Combination therapy for the treatment of ocular neovascular disorders |
| ES2429442T3 (es) * | 2004-02-12 | 2013-11-14 | Archemix Llc | Aptámeros terapéuticos útiles en el tratamiento de trastornos relacionados con complemento |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US20060030535A1 (en) * | 2004-03-05 | 2006-02-09 | Healy Judith M | Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2006265896B2 (en) * | 2005-06-30 | 2012-05-31 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
| US7564805B1 (en) | 2005-08-08 | 2009-07-21 | At&T Intellectual Property, Ii, L.P. | Systems, methods, and device for simulating capacity in a network |
| US9119701B2 (en) | 2012-10-22 | 2015-09-01 | Alcon Research, Ltd. | Pressure control in phacoemulsification system |
| JP6619006B2 (ja) | 2014-08-18 | 2019-12-11 | マグネティカ リミテッド | 頭部及び末端の撮像のための磁石、該磁石を有する核磁気共鳴映像システム及び該磁石の設計方法 |
-
2007
- 2007-03-08 NZ NZ571791A patent/NZ571791A/en not_active IP Right Cessation
- 2007-03-08 SI SI200731744T patent/SI2596807T1/sl unknown
- 2007-03-08 CA CA3148917A patent/CA3148917A1/en active Pending
- 2007-03-08 MX MX2008011323A patent/MX2008011323A/es active IP Right Grant
- 2007-03-08 SG SG2011041449A patent/SG172686A1/en unknown
- 2007-03-08 JP JP2008558415A patent/JP5406534B2/ja active Active
- 2007-03-08 PL PL07752702T patent/PL1991275T3/pl unknown
- 2007-03-08 US US12/224,708 patent/US20090269356A1/en not_active Abandoned
- 2007-03-08 EP EP22194830.0A patent/EP4159220A1/en not_active Withdrawn
- 2007-03-08 ES ES12173138.4T patent/ES2562423T3/es active Active
- 2007-03-08 CA CA3009846A patent/CA3009846C/en active Active
- 2007-03-08 SI SI200731599T patent/SI1991275T1/sl unknown
- 2007-03-08 EP EP07752702.6A patent/EP1991275B1/en active Active
- 2007-03-08 KR KR1020147014128A patent/KR101584468B1/ko active IP Right Grant
- 2007-03-08 PT PT77527026T patent/PT1991275E/pt unknown
- 2007-03-08 DK DK12173138.4T patent/DK2596807T3/en active
- 2007-03-08 AU AU2007223796A patent/AU2007223796B2/en active Active
- 2007-03-08 PT PT121731384T patent/PT2596807E/pt unknown
- 2007-03-08 PL PL12173138T patent/PL2596807T3/pl unknown
- 2007-03-08 DK DK07752702.6T patent/DK1991275T3/en active
- 2007-03-08 ES ES07752702.6T patent/ES2527695T3/es active Active
- 2007-03-08 RU RU2008139901/15A patent/RU2477137C2/ru active
- 2007-03-08 HU HUE12173138A patent/HUE026496T2/en unknown
- 2007-03-08 EP EP17206695.3A patent/EP3360582A1/en not_active Ceased
- 2007-03-08 SG SG2014011290A patent/SG2014011290A/en unknown
- 2007-03-08 EP EP15191232.6A patent/EP3034094A1/en not_active Withdrawn
- 2007-03-08 CA CA2643951A patent/CA2643951C/en active Active
- 2007-03-08 WO PCT/US2007/006020 patent/WO2007103549A2/en active Application Filing
- 2007-03-08 CA CA3009854A patent/CA3009854A1/en not_active Abandoned
- 2007-03-08 CN CN201510087938.6A patent/CN104623692A/zh active Pending
- 2007-03-08 KR KR1020157002274A patent/KR20150017388A/ko not_active Application Discontinuation
- 2007-03-08 SG SG10201706440RA patent/SG10201706440RA/en unknown
- 2007-03-08 EP EP12173138.4A patent/EP2596807B1/en active Active
- 2007-03-08 KR KR1020087024533A patent/KR101513308B1/ko active IP Right Grant
- 2007-03-08 BR BRPI0708588-5A patent/BRPI0708588A2/pt not_active Application Discontinuation
-
2008
- 2008-09-02 IL IL193828A patent/IL193828A/en active IP Right Grant
-
2009
- 2009-05-19 HK HK13108606.4A patent/HK1181308A1/zh unknown
- 2009-05-19 HK HK09104551.4A patent/HK1127281A1/xx unknown
-
2012
- 2012-12-13 RU RU2012153978/15A patent/RU2012153978A/ru not_active Application Discontinuation
-
2013
- 2013-01-15 JP JP2013004412A patent/JP5746232B2/ja active Active
-
2014
- 2014-06-19 JP JP2014126169A patent/JP2014172910A/ja not_active Withdrawn
-
2016
- 2016-07-11 US US15/207,028 patent/US20170145416A1/en not_active Abandoned
- 2016-12-21 HK HK16114526A patent/HK1225996A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009529058A5 (ja) | ||
| RU2008139901A (ru) | Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений | |
| JP2012525415A5 (ja) | ||
| JP2012072152A5 (ja) | ||
| JP2015509500A5 (ja) | ||
| JP2017514917A5 (ja) | ||
| IL310376A (en) | Methods and preparations for the treatment of angiogenic disorders using anti-VEGF agents | |
| JP2019510078A5 (ja) | ||
| US11242367B2 (en) | Silk-derived protein for treating inflammation | |
| RU2009149385A (ru) | АНТИТЕЛА ПРОТИВ С3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ | |
| JP2020530470A5 (ja) | ||
| KR20130099926A (ko) | 염증성 눈질환의 치료/예방용 화합물 | |
| WO2006119128A3 (en) | Vascular targeting of ocular neovascularization | |
| JP2016508372A5 (ja) | ||
| JP2014533274A5 (ja) | ||
| JP2017502023A (ja) | 眼疾患を治療する組成物および方法 | |
| Carracedo et al. | The role of dinucleoside polyphosphates on the ocular surface and other eye structures | |
| Irani et al. | An Anti–VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea | |
| WO2022241255A1 (en) | Extended-wear silicone hydrogel contact lenses and uses thereof | |
| RU2016145136A (ru) | РЕКОМБИНАНТНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА vNAR, НЕЙТРАЛИЗУЮЩИЕ ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ (VEGF) | |
| JP2015514760A5 (ja) | ||
| JP2018530574A5 (ja) | ||
| JP2013523748A5 (ja) | ||
| JPWO2020193999A5 (ja) | ||
| JP2018508528A5 (ja) |